Literature DB >> 22102632

Inhibition of FoxO transcriptional activity prevents muscle fiber atrophy during cachexia and induces hypertrophy.

Sarah A Reed1, Pooja B Sandesara, Sarah M Senf, Andrew R Judge.   

Abstract

Cachexia is characterized by inexorable muscle wasting that significantly affects patient prognosis and increases mortality. Therefore, understanding the molecular basis of this muscle wasting is of significant importance. Recent work showed that components of the forkhead box O (FoxO) pathway are increased in skeletal muscle during cachexia. In the current study, we tested the physiological significance of FoxO activation in the progression of muscle atrophy associated with cachexia. FoxO-DNA binding dependent transcription was blocked in the muscles of mice through injection of a dominant negative (DN) FoxO expression plasmid prior to inoculation with Lewis lung carcinoma cells or the induction of sepsis. Expression of DN FoxO inhibited the increased mRNA levels of atrogin-1, MuRF1, cathepsin L, and/or Bnip3 and inhibited muscle fiber atrophy during cancer cachexia and sepsis. Interestingly, during control conditions, expression of DN FoxO decreased myostatin expression, increased MyoD expression and satellite cell proliferation, and induced fiber hypertrophy, which required de novo protein synthesis. Collectively, these data show that FoxO-DNA binding-dependent transcription is necessary for normal muscle fiber atrophy during cancer cachexia and sepsis, and further suggest that basal levels of FoxO play an important role during normal conditions to depress satellite cell activation and limit muscle growth.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22102632      PMCID: PMC3289501          DOI: 10.1096/fj.11-189977

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  78 in total

Review 1.  Upstream and downstream of mTOR.

Authors:  Nissim Hay; Nahum Sonenberg
Journal:  Genes Dev       Date:  2004-08-15       Impact factor: 11.361

Review 2.  Endotoxins and other sepsis triggers.

Authors:  Steven M Opal
Journal:  Contrib Nephrol       Date:  2010-06-01       Impact factor: 1.580

3.  Anti-TNF treatment reverts increased muscle ubiquitin gene expression in tumour-bearing rats.

Authors:  M Llovera; N Carbó; C García-Martínez; P Costelli; L Tessitore; F M Baccino; N Agell; G J Bagby; F J López-Soriano; J M Argilés
Journal:  Biochem Biophys Res Commun       Date:  1996-04-25       Impact factor: 3.575

4.  Sepsis upregulates the gene expression of multiple ubiquitin ligases in skeletal muscle.

Authors:  Curtis J Wray; Joshua M V Mammen; Dan D Hershko; Per-Olof Hasselgren
Journal:  Int J Biochem Cell Biol       Date:  2003-05       Impact factor: 5.085

5.  C/EBP DNA-binding activity is upregulated by a glucocorticoid-dependent mechanism in septic muscle.

Authors:  Gail Penner; Gyu Gang; Xiaoyan Sun; Curtis Wray; Per-Olof Hasselgren
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2002-02       Impact factor: 3.619

6.  A potential role for Akt/FOXO signalling in both protein loss and the impairment of muscle carbohydrate oxidation during sepsis in rodent skeletal muscle.

Authors:  Hannah Crossland; Dumitru Constantin-Teodosiu; Sheila M Gardiner; Despina Constantin; Paul L Greenhaff
Journal:  J Physiol       Date:  2008-09-25       Impact factor: 5.182

7.  Skeletal muscle FOXO1 (FKHR) transgenic mice have less skeletal muscle mass, down-regulated Type I (slow twitch/red muscle) fiber genes, and impaired glycemic control.

Authors:  Yasutomi Kamei; Shinji Miura; Miki Suzuki; Yuko Kai; Junko Mizukami; Tomoyasu Taniguchi; Keiji Mochida; Tomoko Hata; Junichiro Matsuda; Hiroyuki Aburatani; Ichizo Nishino; Osamu Ezaki
Journal:  J Biol Chem       Date:  2004-07-21       Impact factor: 5.157

8.  The glucocorticoid receptor and FOXO1 synergistically activate the skeletal muscle atrophy-associated MuRF1 gene.

Authors:  David S Waddell; Leslie M Baehr; Jens van den Brandt; Steven A Johnsen; Holger M Reichardt; J David Furlow; Sue C Bodine
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-07-08       Impact factor: 4.310

9.  Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group.

Authors:  W D Dewys; C Begg; P T Lavin; P R Band; J M Bennett; J R Bertino; M H Cohen; H O Douglass; P F Engstrom; E Z Ezdinli; J Horton; G J Johnson; C G Moertel; M M Oken; C Perlia; C Rosenbaum; M N Silverstein; R T Skeel; R W Sponzo; D C Tormey
Journal:  Am J Med       Date:  1980-10       Impact factor: 4.965

10.  FKHR-L1 can act as a critical effector of cell death induced by cytokine withdrawal: protein kinase B-enhanced cell survival through maintenance of mitochondrial integrity.

Authors:  Pascale F Dijkers; Kim U Birkenkamp; Eric W-F Lam; N Shaun B Thomas; Jan-Willem J Lammers; Leo Koenderman; Paul J Coffer
Journal:  J Cell Biol       Date:  2002-01-28       Impact factor: 10.539

View more
  86 in total

1.  SIRT1 protein, by blocking the activities of transcription factors FoxO1 and FoxO3, inhibits muscle atrophy and promotes muscle growth.

Authors:  Donghoon Lee; Alfred L Goldberg
Journal:  J Biol Chem       Date:  2013-09-03       Impact factor: 5.157

Review 2.  FoxO transcription factors: their roles in the maintenance of skeletal muscle homeostasis.

Authors:  Anthony M J Sanchez; Robin B Candau; Henri Bernardi
Journal:  Cell Mol Life Sci       Date:  2014-05       Impact factor: 9.261

Review 3.  Mitophagy in tumorigenesis and metastasis.

Authors:  Logan P Poole; Kay F Macleod
Journal:  Cell Mol Life Sci       Date:  2021-02-13       Impact factor: 9.261

Review 4.  Skeletal muscle atrophy and the E3 ubiquitin ligases MuRF1 and MAFbx/atrogin-1.

Authors:  Sue C Bodine; Leslie M Baehr
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-08-05       Impact factor: 4.310

5.  Understanding tumor anabolism and patient catabolism in cancer-associated cachexia.

Authors:  Alejandro Schcolnik-Cabrera; Alma Chávez-Blanco; Guadalupe Domínguez-Gómez; Alfonso Dueñas-González
Journal:  Am J Cancer Res       Date:  2017-05-01       Impact factor: 6.166

6.  NF-κB but not FoxO sites in the MuRF1 promoter are required for transcriptional activation in disuse muscle atrophy.

Authors:  Chia-Ling Wu; Evangeline W Cornwell; Robert W Jackman; Susan C Kandarian
Journal:  Am J Physiol Cell Physiol       Date:  2014-02-19       Impact factor: 4.249

Review 7.  Sirtuins-Mediated System-Level Regulation of Mammalian Tissues at the Interface between Metabolism and Cell Cycle: A Systematic Review.

Authors:  Parcival Maissan; Eva J Mooij; Matteo Barberis
Journal:  Biology (Basel)       Date:  2021-03-04

Review 8.  Mechanisms for fiber-type specificity of skeletal muscle atrophy.

Authors:  Yichen Wang; Jeffrey E Pessin
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2013-05       Impact factor: 4.294

9.  HDAC1 activates FoxO and is both sufficient and required for skeletal muscle atrophy.

Authors:  Adam W Beharry; Pooja B Sandesara; Brandon M Roberts; Leonardo F Ferreira; Sarah M Senf; Andrew R Judge
Journal:  J Cell Sci       Date:  2014-01-24       Impact factor: 5.285

10.  Investigation of novel LPS-induced differentially expressed long non-coding RNAs in endothelial cells.

Authors:  Krishna K Singh; Pratiek N Matkar; Shoaib Muhammad; Adrian Quan; Vijay Gupta; Hwee Teoh; Mohammed Al-Omran; Subodh Verma
Journal:  Mol Cell Biochem       Date:  2016-08-26       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.